-
Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension
•
China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced the clinical results for the Iberis-HTN trial at the China Interventional Therapeutics 2023 conference. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial designed to evaluate the safety and efficacy of the Iberis Multi-Electrode Renal…
-
Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study
•
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal radiofrequency denervation (RDN) system has successfully reached its primary clinical endpoint in the randomized, controlled Iberis-HTN study for the treatment of primary hypertension. Iberis-HTN Study ResultsThe prospective, multicenter, blinded, randomized controlled trial was designed to…
-
Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France
•
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment in the RADIUS-HTN study for its Iberis renal radiofrequency denervation (RDN) system, marking a significant milestone in Bordeaux, France. Objectives and Design of the RADIUS-HTN StudyThe RADIUS-HTN study is designed to assess the performance of…
